Publications
2024
Sep 30 2024
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Arne Claeys and Jimmy Van den Eynden
Jan 11, 2024
Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN
Jonatan L Gabre, Peter Merseburger, Arne Claeys, Joachim Siaw, Sarah-Lee Bekaert, Frank Speleman, Bengt Hallberg, Ruth H Palmer and Jimmy Van den Eynden
2023
Dec 28, 2023
ALK signaling primes the DNA damage response sensitizing ALK-driven neuroblastoma to therapeutic ATR inhibition
Marcus Borenäs, Ganesh Umapathy, Dan E. Lind, Wei-Yun Lai, Jikui Guan, Joel Johansson, Eva Jennische, Alexander Schmidt, Yeshwant Kurhe, Jonatan L. Gabre, Agata Aniszewska, Anneli Strömberg, Mats Bemark, Michael N. Hall, Jimmy Van den Eynden, Bengt Hallberg and Ruth H. Palmer
Dec 12, 2023
A computational exploration of MHC-based immune selection signals in large cancer genome sequencing datasets
Arne Claeys
May 10, 2023
A systematic analysis of immune escape signals in the primary and metastatic tumor genome
Jimmy Van den Eynden
May 09, 2023
Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data
Arne Claeys, Peter Merseburger, Jasper Staut, Kathleen Marchal and Jimmy Van den Eynden
Mar 15, 2023
Quantification of Neoantigen-Mediated Immunoediting in Cancer Evolution
Arne Claeys, Jimmy Van den Eynden
Feb 15, 2023
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Tzu-Po Chuang, Wei-Yun Lai, Jonatan Gabre, Dan E. Lind, Ganesh Umapathy, Abdulmalik A. Bokhari, Bengt Bergman, Linnea Kristenson, Fredrik B. Thorén, Anh Le, Robert C. Doebele, Jimmy Van den Eynden, Ruth H. Palmer and Bengt Hallberg
2022
Jul 24, 2022
Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC
A.A. Bokhari, W-Y. Lai, A.T. Le, Jonatan Gabre, T-P. Chuang, S. Fransson, B. Bergman, A. Djos, N. Chen, T. Martinsson, Jimmy Van den Eynden, R.C. Doebele, R.H. Palmer, B. Hallberg and G. Umapathy
Jun 20, 2022
A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues
Tom Luijts, Kerryn Elliott, Joachim Siaw, Joris Van de Velde, Elien Beyls, Arne Claeys, Tim Lammens, Erik Larsson, Wouter Willaert, Anne Vral and Jimmy Van den Eynden
2021
Nov 24, 2021
ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
Joanna Szydzik, Dan E. Lind, Badrul Arefin, Yeshwant Kurhe, Ganesh Umapathy, Joachim Siaw, Arne Claeys, Jonatan Gabre, Jimmy Van den Eynden, Bengt Hallberg and Ruth H. Palmer
Oct 28, 2021
Pharmacologic RNA splicing modulation: a novel mechanism to enhance neoantigen-directed anti-tumor immunity and immunotherapy response
Kerryn Elliott, Jonas Nilsson and Jimmy Van den Eynden
Oct 21, 2021
Network-Based Analysis to Identify Drivers of Metastatic Prostate Cancer Using GoNetic
Louise de Schaetzen van Brienen, Giles Miclotte, Maarten Larmuseau, Jimmy Van den Eynden and Kathleen Marchal
Apr 15, 2021
Loss of RET promotes mesenchymal identity in neuroblastoma cells
Joachim T. Siaw, Jonatan Gabre, Ezgi Uçkun, Marc Vigny, Wancun Zhang, Jimmy Van den Eynden, Bengt Hallberg, Ruth H. Palmer and Jikui Guan
Feb 8, 2021
Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals
Arne Claeys, Tom Luijts, Kathleen Marchal and Jimmy Van den Eynden
Jan 7, 2021
ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
Marcus Borenäs, Ganesh Umapathy, Wei‐Yun Lai, Dan E Lind, Barbara Witek, Jikui Guan, Patricia Mendoza‐Garcia, Tafheem Masudi, Arne Claeys, Tzu‐Po Chuang, Abeer El Wakil, Badrul Arefin, Susanne Fransson, Jan Koster, Mathias Johansson, Jennie Gaarder, Jimmy Van den Eynden, Bengt Hallberg and Ruth H Palmer
2020
Sep 22, 2020
11q Deletion or ALK Activity Curbs DLG2 Expression to Maintain an Undifferentiated State in Neuroblastoma
Joachim Tetteh Siaw, Niloufar Javanmardi, Jimmy Van den Eynden, et al.
Jan 11, 2020
Separating positional noise from neutral alignment in multicomponent statistical shape models
Emmanuel Audenaert, Jimmy Van den Eynden, DF de Almeida, G Steenackers, D Vandermeulen and P Claes
2019
Nov 25, 2019
Lack of detectable neoantigen depletion signals in the untreated cancer genome
Jimmy Van den Eynden, Alejandro Jiménez-Sánchez, Martin L Miller and Erik Larsson
Apr 24, 2019
Targeting filamin A reduces macrophage activity and atherosclerosis
Sashidar Bandaru, Chandu Ala, Reza Salimi, Murali K. Akula, Matias Ekstrand, Sravani Devarakonda, Joakim Karlsson, Jimmy Van den Eynden, Göran Bergström, Erik Larsson, Max Levin, Jan Borén, Martin O. Bergo and Levent M. Akyürek
2018
Dec 26, 2018
Elevated pyrimidine dimer formation at distinct genomic bases underlies promoter mutation hotspots in UV-exposed cancers
Kerryn Elliott, Martin Boström, Stefan Filges, Markus Lindberg, Jimmy Van den Eynden, Anders Ståhlberg, Anders R Clausen and Erik Larsson